603127 昭衍新藥
按盤價 
36.660 +0.210 (+0.576%) | 2025/12 - 人民幣(K¥) | 變動 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 1,657,624 | -17.87% | 2,376,487 | 2,267,971 | 1,516,680 | 1,075,905 | |
| 減：營業總成本 | 1,663,215 | -5.70% | 1,622,010 | 1,418,766 | 1,086,978 | 804,306 | |
| 其中:營業成本 | 1,314,312 | -9.02% | 1,363,701 | 1,181,660 | 777,558 | 523,092 | |
| 財務費用 | (66,802) | -33.05% | (151,091) | (154,682) | (19,156) | 2,477 | |
| 資產減值損失 | (156,761) | 135.59% | (31,232) | (2,792) | (1,331) | (1,510) | |
| 公允價值變動收益 | 447,560 | -452.27% | (245,642) | 349,567 | 157,777 | 58,946 | |
| 投資收益 | 18,014 | -49.98% | 9,628 | 13,022 | 17,000 | 1,524 | |
| 其中：對聯營企業和合營企業的投資收益 | -- | -- | (3,069) | (2,691) | (426) | -- | |
| 營業利潤 | 337,991 | 223.91% | 507,096 | 1,225,639 | 642,889 | 361,118 | |
| 利潤總額 | 337,493 | 224.39% | 506,950 | 1,240,002 | 642,004 | 360,572 | |
| 減：所得稅費用 | 39,651 | 15.65% | 115,398 | 166,802 | 85,587 | 46,944 | |
| 淨利潤 | 297,843 | 326.98% | 391,553 | 1,073,200 | 556,416 | 313,628 | |
| 減：非控股權益 | 1 | -100.03% | (5,440) | (1,057) | (1,043) | (1,386) | |
| 股東淨利潤 | 297,841 | 302.08% | 396,993 | 1,074,257 | 557,460 | 315,014 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.400 | 300.00% | 0.530 | 1.440 | 1.080 | 1.000 | |
| 每股派息 (元) * | 0.120 | 300.00% | 0.160 | 0.400 | 0.360 | 0.350 | |
| 每股淨資產 (元) * | 11.108 | 3.05% | 11.040 | 15.277 | 18.720 | 5.390 | |
| 審計意見 # | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 03/04/2026 11:08 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
